VF
MLTX icon

Virtu Financial’s MoonLake Immunotherapeutics MLTX Stock Holding History

Virtu Financial’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$196K Sell
10,526
-2,056
-16% -$34.1K 0.01% 1031
2025
Q4 		$166K Buy
+12,582
New +$148K 0.01% 1081
2023
Q1 		– Sell
-14,395
Closed -$151K – 1851
2022
Q4 		$151K Buy
+14,395
New +$128K 0.02% 814

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Virtu Financial's MLTX Position: Q1 2026 in Review

Virtu Financial reduced its MoonLake Immunotherapeutics (MLTX) stake by 16% in Q1 2026, selling an estimated $34.1K and leaving 10,526 shares worth $196K. The position accounts for 0.01% of the portfolio, ranked #1031.

Virtu Financial first reported a position in MLTX in Q4 2022 and has held it in 3 quarters since. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

  • Virtu Financial held 10,526 shares of MoonLake Immunotherapeutics worth $196K as of Q1 2026.
  • Virtu Financial sold 2,056 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $34.1K.
  • MoonLake Immunotherapeutics made up 0.01% of Virtu Financial's portfolio in Q1 2026, its #1031 holding.
  • Virtu Financial first reported a position in MoonLake Immunotherapeutics in Q4 2022 and has held it in 3 quarters since.
  • 147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Virtu Financial's 13F filing for Q1 2026, filed 14 May 2026.